Design Therapeutics (DSGN) Capital Expenditures (2020 - 2025)

Design Therapeutics (DSGN) has 6 years of Capital Expenditures data on file, last reported at $34000.0 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $34000.0; the trailing twelve-month figure through Mar 2026 stood at $121000.0 (down 44.24% YoY), and the FY2025 full-year result was $193000.0, down 43.24% from the prior year.
• Capital Expenditures fell to $34000.0 in Q4 2025, from $87000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $968000.0 in Q3 2021 to a low of -$204000.0 in Q4 2023.
• A 5-year average of $167444.4 and a median of $87000.0 in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 2428.57% in 2021 and plunged 130.19% in 2024, its largest moves.
• Tracing DSGN's Capital Expenditures over 5 years: stood at $354000.0 in 2021, then soared by 142.66% to $859000.0 in 2022, then sank by 123.75% to -$204000.0 in 2023, then jumped by 92.16% to -$16000.0 in 2024, then soared by 312.5% to $34000.0 in 2025.
• Business Quant data shows DSGN's Capital Expenditures at $34000.0 in Q4 2025, $87000.0 in Q2 2025, and $72000.0 in Q1 2025.